183 related articles for article (PubMed ID: 38229462)
1. Testosterone replacement therapy: clinical considerations.
Luther PM; Spillers NJ; Talbot NC; Sinnathamby ES; Ellison D; Kelkar RA; Ahmadzadeh S; Shekoohi S; Kaye AD
Expert Opin Pharmacother; 2024; 25(1):25-35. PubMed ID: 38229462
[TBL] [Abstract][Full Text] [Related]
2. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
3. Late-life onset hypogonadism: a review.
Bassil N; Morley JE
Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
[TBL] [Abstract][Full Text] [Related]
4. [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].
Rinnab L; Gust K; Hautmann RE; Küfer R
Urologe A; 2009 May; 48(5):516-22. PubMed ID: 19296069
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Therapy: What We Have Learned From Trials.
Corona G; Torres LO; Maggi M
J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
[TBL] [Abstract][Full Text] [Related]
6. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
Borst SE; Yarrow JF
Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
[TBL] [Abstract][Full Text] [Related]
7. An update on male hypogonadism therapy.
Surampudi P; Swerdloff RS; Wang C
Expert Opin Pharmacother; 2014 Jun; 15(9):1247-64. PubMed ID: 24758365
[TBL] [Abstract][Full Text] [Related]
8. 'Forever Young'-Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises.
Busnelli A; Somigliana E; Vercellini P
Hum Reprod; 2017 Apr; 32(4):719-724. PubMed ID: 28333214
[TBL] [Abstract][Full Text] [Related]
9. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis.
Elliott J; Kelly SE; Millar AC; Peterson J; Chen L; Johnston A; Kotb A; Skidmore B; Bai Z; Mamdani M; Wells GA
BMJ Open; 2017 Nov; 7(11):e015284. PubMed ID: 29150464
[TBL] [Abstract][Full Text] [Related]
10. Gaps in Patient Knowledge About Risks and Benefits of Testosterone Replacement Therapy.
Gilbert K; Cimmino CB; Beebe LC; Mehta A
Urology; 2017 May; 103():27-33. PubMed ID: 28238756
[TBL] [Abstract][Full Text] [Related]
11. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
12. The benefits and risks of testosterone replacement therapy: a review.
Bassil N; Alkaade S; Morley JE
Ther Clin Risk Manag; 2009 Jun; 5(3):427-48. PubMed ID: 19707253
[TBL] [Abstract][Full Text] [Related]
13. Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
Lazarou S; Morgentaler A
Curr Urol Rep; 2005 Nov; 6(6):476-81. PubMed ID: 16238923
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
16. Testosterone and aging male, a perspective from a developing country.
Nguyen Hoai B; Hoang L; Nguyen Cao T; Pham Minh Q; A Jannini E
Aging Male; 2023 Dec; 26(1):2223712. PubMed ID: 37335039
[TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
19. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
20. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
Jensen CF; Fode M; Østergren P; Sønksen J
Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
